Moving from Preclinical to Clinical Applications of Hyperpolarised MRI: Successes & Challenges
Member-Initiated Symposium

ORGANIZERS: Arnaud Comment, Bastiaan Driehuys, Christoffer Laustsen

Thursday, 21 June 2018

Session Number: MIS-22

Overview
This Symposium was proposed by the Hyperpolarized Media MR study group.

A rapidly growing number of sites are performing clinical MRI scans with hyperpolarized (HP) gases or metabolic substrates worldwide. HP 129Xe MRI and HP 13C MRI are used for distinct applications and use dramatically different techniques and hardware to prepare their respective HP medium. However, they share some similarities because both require fast and sensitive acquisition hardware and software

The HP 129Xe gas community has already initiated multisite clinical trials while the investigators working with HP 13C-substrates have yet to define the first comparative studies. We therefore believe that the ISMRM 2018 meeting provides a timely opportunity to bring those two communities together to discuss and share the challenges linked to the translation of HP MRI to wider clinical applications.
We aim at promoting an open dialog that should captivate both MDs and PhDs interested in hyperpolarization. In particular, we will discuss the various successes that have allowed these technologies to go from preclinical to human applications and debate the relevancy of current and future preclinical HP MR studies.
Four experts in both HP fields will share their experience (4 x 20 min talks). These presentations will be followed by a round table discussion moderated by the members of the HP Media Study group committee. Additional world experts will be included in this round table debate, with a key focus on answering questions from the audience.

Target Audience
All MDs and PhDs interested in implementing and translating hyperpolarized MRI.

Educational Objectives
As a result of attending this course, participants should be able to:
- Recognize the challenges related to the implementation of hyperpolarized MRI in a clinical environment; and
- Identify the challenges inherent to clinical trials based on X-nuclei MRI.